Patients with Type 1 Diabetes from the Mediterranean Region Who also have Comorbid Autoimmune Illnesses and Experience the Burden of Diabetes-Related Difficulties

Gabriele–Peroz*

Endocrinology Section, Department of Medicine, Hospital General de Granollers, Granollers, Spain

Corresponding Author*

Gabriele–Peroz

Endocrinology Section, Department of Medicine, Hospital General de Granollers, Granollers, Spain

E-mail: gperoz@fphag.org

Received: 27-Mar-2023, Manuscript No: jdm-23-23700, **Editor assigned:** 30-Mar-2023, Pre QC No: jdm-23-23700 (PQ), **Reviewed:** 13-Apr-2023, QC No: jdm-23-23700, **Revised:** 20-Apr-2023, Manuscript No: jdm-23-23700 (R), **Published:** 28-Apr-2023, DOI: 10.35248/2155-6156.1000996

Abstract

Aim: To determine whether the rate of diabetes-related complications differs depending on the presence of autoimmune diseases (AID) in patients with type 1 diabetes (T1D).

Methods: Cross-sectional analysis of 13,570 SIDIAP-registered T1D patients under the age of 18 The relationship among Help and diabetes-related intricacies was evaluated by multivariable strategic relapse models.

Results: AID was present 18.3% of the time, with thyroid AID being the most common. Females were more common among T1D and AID patients, and their current age, age at onset, and duration of diabetes were all higher. Patients with just thyroid Guide encountered a lower chance of fringe conduit infection (chances proportion [OR] = 0.51, 95%; certainty stretch [CI] 0.31 to 0.81) and kidney illness (OR = 0.68, 95%; In contrast, patients with other AID had a higher risk of ischemic heart disease (OR = 1.48, 95 percent; 95% CI 1.04 to 2.06).

Conclusions: Depending on the type of additional AID, the prevalence of diabetes-related complications in T1D patients varies. Diabetes complications are less common in people with autoimmune thyroid disease, whereas ischemic heart disease is more common in people with other AID.

Keywords: Type 1 diabetes mellitus; Autoimmunity; Glycemic control; Diabetes complications

Introduction

Type 1 diabetes (T1D) is a regular immune system infection with and assessed predominance of 9 million individuals overall. T1D is characterized by the need for lifelong insulin treatment due to the destruction of pancreatic islet cells. Patients with T1D face significant disease-related distress as well as an increased risk of microvascular and macrovascular complications. T1D patients have a high prevalence of other AIDs, both endocrine and non-endocrine, which adds morbidity and treatment complexity to an already significant disease burden [1]. The study of disease transmission and hazard factors for microvascular and macrovascular complexities in T1D patients have been widely considered, however less consideration has been paid to the presence of comorbid Helps and their effect on the presence of entanglements. In patients with T1D, metabolic control may be negatively affected by additional autoimmune diseases, potentially increasing the risk of micro- or macrovascular complications. The prevalence of cardiovascular disorders related to the presence of additional AIDs in patients with T1D is either higher or lower and the prevalence of microvascular complications in the presence of additional AIDs shows conflicting results [2]. Furthermore, the majority of autoimmune diseases confer an increased risk of cardiovascular disease, which could increase the already high baseline cardiovascular risk of T1D. Existing data on this subject are contentious and show either a higher prevalence of cardiovascular disorders related to the presence

North America Northern Europe, and Germany-Austria] have conducted the largest studies that have characterized various aspects of T1D patients who also have AIDs. In any case, the predominance of Helps and their concurrence with T1D might be dependent upon geological contrasts and, as far as anyone is concerned, up until this point no examinations have been performed on the connection among T1D and its constant complexities with different Guides in the Mediterranean region [3].

Materials and Methods

Patients with T1D who were registered in the SIDIAP database were the subjects of this retrospective, cross-sectional study. Recently, a detailed description of the SIDIAP database and the method by which T1D patients were identified in the database were published [4]. Momentarily, SIDIAP is an essential medical care data set which catches anonymized data of roughly 5.8 million individuals in Catalonia enlisted with a family doctor from the Institut Català de la Salut (ICS, Catalan Foundation of Wellbeing). Around 75% of the Catalan population, which is representative of the entire population of Catalonia in terms of age, geography, and sex, receives primary health care from ICS. The ICS and CatSalut databases guarantee that, regardless of where clinical care is provided, the registry of patients with T1D of any age can be considered complete [5]. Although T1D patients typically receive care in a hospital-based specialist care setting, primary care centers also provide prescriptions for chronic medications and glucose control supplies. SIDIAP incorporates information from the normal essential consideration electronic clinical records (socioeconomics, analyze, clinical factors, solutions, references and research center outcomes). It also includes information about hospital discharges from the Basic Minimum Set of Data (BMSD) and medications that are given out in pharmacy offices. Several observational studies evaluating the clinical characteristics and outcomes of Type 1 and Type 2 diabetes in Catalonia have previously utilized the SIDIAP database [6].

We recovered information from subjects more established than 18 years with an enrolled conclusion of T1D (Worldwide Characterization of Sicknesses 10 [ICD-10] code E10) preceding January 1, 2017 with no corresponding determination of different sorts of diabetes (E11, E13, E14). We used restrictive criteria to exclude patients with an E10 diagnosis who were not treated with short-acting insulins more than two years after the registered date of diagnosis and those who were treated with glucose-lowering agents other than insulin [7]. These prohibitive models depended on records of prescriptions recovered at drug stores during the information assortment period from January 1, 2016 through December 31, 2016, consequently restricting the cross-sectional companion to patients who had reached the ICS framework during this period. Unless otherwise specified, the most recent registered measure was taken in 2016. Age, gender, duration of diabetes (2016 minus year of diabetes diagnosis), HbA1c (mean of all values available during the study period), estimated glomerular filtration rate (GFR) using the CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) formula, and urinary albumin/creatinine ratio

were all collected for this analysis. Enrolled finding of T1D difficulties were recovered involving ICD-10 codes as recently portrayed [8].

Results

The final sample included 13,570 T1D patients over the age of 18 (mean SD, 45.2 15.3 years). There were 7,745 men (57.1%) and 5,826 women (42.9%) in the sex distribution. At the time of diagnosis, the average age was 31.7 16.5 years, and the average duration of diabetes was 14.1 9.9 years.

Clinical characteristics of additional AIDS

The prevalence of additional autoimmune diseases was 18.3% in this study population (95 percent CI, 17.6% to 18.9%). Additional AID had a significantly shorter mean time since diagnosis than T1D (8.0 6.6 vs. 14.1 9.9; $p < 0.001$).

Females were more likely to have T1D and additional AID, and their current age, age at onset, and duration of diabetes were all higher than those of patients without additional AID [9].

We found 239 (9.6%) patients with two additional AIDs, 21 (0.8%) with three or more additional AIDs, and 89.5% (2,225) of the autoimmune disease patients had only one additional AID.

Again, patients who had more than one AID were more likely to be female (71.1%), older (49.7 15.5 years compared to 45.2 15.3 years for those without AID), and had diabetes for a longer period of time (16.1 11 years compared to 14.1 9.9).

Hypothyroidism, which was clearly more common in women, was the most common autoimmune disease. Except for "diseases of the skin and subcutaneous tissue," where no differences were observed, this was again higher in women for the remaining AIDs with a prevalence sufficient to demonstrate differences [10].

Extra guides Glycemic control and diabetes confusions

Patients with extra Guide are isolated in two gatherings as per the presence of just thyroid immune system problems or different Guides (whether with thyroid sickness). During the study year, mean HbA1c levels reflected glucose control. There were significant differences between groups, but they were not clinically relevant. In any case, glucose control was slightly better in patients with additional AIDs who also had a lower prevalence of smoking (either ex-smokers or current smokers).

Ischemic heart disease was more common in patients with any AID (23.2%), with a 95% confidence interval of 20.1% to 26.5%. Be that as it may, this distinction was not critical in the calculated relapse examination adapted to mature, sex, diabetes length, dyslipidemia, hypertension and smoking.

The prevalence of kidney disease and peripheral artery disease was significantly lower in patients with only thyroid autoimmune disorders. Retinopathy, neuropathy, ischemic heart disease, and cerebrovascular disease were more prevalent in patients with other AID than in those with thyroid autoimmune disorders [11].

Discussion

The primary finding of this cross-sectional concentrate in a huge example of subjects with T1D from a Mediterranean region is that the weight of diabetes-related complexities varies as per the presence of extra Guides. In particular, the presence of secluded immune system thyroid sickness is related with a lower commonness of kidney illness and fringe conduit illness, though the presence of different Guides is related with a higher predominance of ischemic coronary illness [12].

Compared to other studies from Finland or the United States with prevalences of around 25%, this study's prevalence of additional AIDs is lower, particularly for thyroid diseases. However, it is higher than the one described in a recent study from Germany, which reported a prevalence of thyroid disease of 5.7% in younger T1D patients. The majority of studies show that the prevalence of additional AIDs, particularly hypothyroidism, increases with age, and the age at which T1D is diagnosed [13]. As a result, differences in prevalence may be related to the age of the study population. In any case, the age qualities don't legitimize these distinctions since current age in our populace in the middle of between different reports with a higher commonness of Helps and the age at finding is reliably higher than in different examinations. In addition, our cohort has a lower proportion of women, who are particularly susceptible to AID, than in other studies but is comparable to other studies [5]; our discoveries are likewise steady with the frequency paces of T1D as per sex in Catalonia . Variations in genetic and environmental risk factors, which may also differ for T1D in comparison to other AIDs [18], may also be a factor in regional variations in AIDs prevalence [14]. Our somewhat discordant results may also have been influenced by the diversity of screening procedures. In patients with T1D, evaluating for asymptomatic or oligosymptomatic immune system sicknesses, for example, immune system thyroiditis, celiac illness and malevolent pallor is by and large suggested with a sensibly level of proof, and continued screening methods in asymptomatic patients have been displayed to prompt a higher commonness, to some degree on account of immune system thyroid problems. However, healthcare providers may be discouraged from implementing these recommendations due to the lack of solid evidence on the benefits of these strategies, resulting in underdiagnosis of these conditions [15].

Limitations

There are some limitations to this study. We cannot rule out the possibility of underreporting of diabetes complications or autoimmune diseases, particularly those unrelated to specific treatments like chronic autoimmune thyroiditis or celiac disease, as we relied on registered codes without external validation measures. These are typical drawbacks of the current electronic record databases for primary care, highlighting the need for additional validation studies with external databases, the creation of internal control algorithms, and comparing the findings to those of other studies of a similar nature. Additionally, we cannot rule out the possibility of misdiagnosing other types of diabetes—particularly pancreatic diabetes, which is typically treated solely with insulin—as type 1, which would reduce the proportion of patients at risk for other autoimmune conditions. Additionally, because ICD10 codes do not differentiate this type of diabetes, we were unable to identify patients with latent autoimmune diabetes (LADA). Patients with LADA ought to probably be named T1D yet misclassification is successive, and their weight of diabetes-related entanglements and attendant Guides might be not the same as that of traditional T1D.

Another significant limitation is the proportion of laboratory parameter missing data. This may be because only ICS hospitals automatically transfer laboratory data to the SIDIAP database, while most T1D patients are managed at the hospital level by health care providers other than ICS. Additionally, it is possible that no clinical or laboratory evaluation was carried out during the study year. Additionally, the evaluation of the relationship between AID and diabetes-related complications is limited by the cross-sectional design of the study, selection bias (due to the exclusion of deceased patients presumably with more complications), and temporality bias. Other than these constraints, our review incorporates an enormous populace of subjects which makes its discoveries important.

Acknowledgement

None

Conflict of Interest

None

References

1. Green A, Hede SM, Patterson CC, Wild SH, Imperatore G, Roglic G, et al. Type 1 diabetes in 2017: global estimates of incident and prevalent cases in children and adults. Diabetologia. 2021; 64: 2741-2750.
2. Fisher L, Hessler D, Polonsky W, Strycker L, Masharani U, Peters A. Diabetes distress in adults with type 1 diabetes: prevalence, incidence and change over time. J Diabetes Complications. 2016; 30: 1123-1128.
3. Hughes JW, Riddlesworth TD, DiMeglio LA, Miller KM, Rickels MR, McGill JB. T1D Exchange Clinic Network. Autoimmune diseases in children and adults with Type 1 diabetes from the T1D exchange clinic registry. J Clin Endocrinol Metab. 2016; 101: 4931-4937.

4. Bao YK, Weide LG, Ganesan VC, Jakhar I, McGill JB, Sahil S, et al. High prevalence of comorbid autoimmune diseases in adults with Type 1 diabetes from the HealthFacts database. J Diabetes. 2019; 11: 273-279.

5. Mäkimattila S, Harjutsalo V, Forsblom C, Groop PH. FinnDiane Study Group. every fifth individual with type 1 diabetes suffers from an additional autoimmune disease: a Finnish nationwide study. Diabetes Care. 2020; 43: 1041-1047.

6. Adamsson Eryd S, Svensson AM, Franzén S, Eliasson B, Nilsson PM, Gudbjörnsdottir S. Risk of future microvascular and macrovascular disease in people with Type 1 diabetes of very long duration: a national study with 10-year follow-up. Diabet Med. 2017; 34: 411-418.

7. Bjerg L, Hulman A, Carstensen B, Charles M, Witte DR, Jørgensen ME. Effect of duration and burden of microvascular complications on mortality rate in type 1 diabetes: an observational clinical cohort study. Diabetologia. 2019; 62: 633-643.

8. Głowinska-Olszewska B, Borysewicz-Sańczyk H, Sawicka B, Klonowska B, Charemska D, Żelazowska-Rutkowska B, et al. Does Hashimoto's thyroiditis increase the risk of cardiovascular disease in young Type 1 diabetic patients? Front Endocrinol (Lausanne). 2020; 11: 431.

9. Ogarek N, Mrówka A, Jarosz-Chobot P. Thyroid diseases - ally or enemy of type 1 diabetes in children and adolescents? Pediatr Endocrinol Diabetes Metab. 2021; 27: 117-122.

10. Dregan A, Charlton J, Chowienczyk P, Gulliford MC. Chronic inflammatory disorders and risk of Type 2 diabetes mellitus, coronary heart disease, and stroke: a population-based cohort study. Circulation. 2014; 130: 837-844.

11. Nona P, Russell C. Cardio-Rheumatology: Prevention of cardiovascular disease in inflammatory disorders. Med Clin North Am. 2022; 106: 349-363.

12. Rogers MAM, Wei MY, Kim C, Lee JM. Sex differences in autoimmune multimorbidity in Type 1 diabetes mellitus and the risk of cardiovascular and renal disease: a longitudinal study in the United States, 2001–2017. J Womens Health (Larchmt). 2020; 29: 511-519.

13. Cardinez N, Lovblom LE, Orszag A, Cherney DZI, Perkins BA. The prevalence of autoimmune diseases in longstanding diabetes: results from the Canadian study of longevity in adults with Type 1 diabetes. Can J Diabetes. 2021; 45: 512-518.

14. Rogowicz-Frontczak A, Falkowski B, Grzelka-Wozniak A, Uruska A, Araszkiewicz A, Zozulinska-Ziolkiewicz D. Does autoimmune hypothyroidism increase the risk of neurovascular complications in Type 1 diabetes? J Endocrinol Invest. 2020; 43: 833-839.

15. Prinz N, Tittel SR, Bachran R, Birnbacher R, Brückel J, Dunstheimer D, et al. Characteristics of patients with Type 1 diabetes and additional autoimmune disease in the DPV registry. J Clin Endocrinol Metab. 2021; 106: 3381-3389.

Cite this article: Gabriele–Peroz. Patients with Type 1 Diabetes from the Mediterranean Region Who also have Comorbid Autoimmune Illnesses and Experience the Burden of Diabetes-Related Difficulties. J Diabetes Metab, 2023, 14(4): 996.